These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 12707224

  • 1. Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis.
    Finazzi G, Ruggeri M, Rodeghiero F, Barbui T.
    Blood; 2003 May 01; 101(9):3749. PubMed ID: 12707224
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of hydroxyurea in patients with essential thrombocythemia.
    Finazzi G, Barbui T.
    Pathol Biol (Paris); 2001 Mar 01; 49(2):167-9. PubMed ID: 11317964
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR, United Kingdom Medical Research Council Primary Thrombocythemia 1 Study.
    N Engl J Med; 2005 Jul 07; 353(1):33-45. PubMed ID: 16000354
    [Abstract] [Full Text] [Related]

  • 5. When and how to treat essential thrombocythemia.
    Barbui T, Finazzi G.
    N Engl J Med; 2005 Jul 07; 353(1):85-6. PubMed ID: 16000360
    [No Abstract] [Full Text] [Related]

  • 6. Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
    Landolfi R, Di Gennaro L.
    Haematologica; 2008 Mar 07; 93(3):331-5. PubMed ID: 18310537
    [No Abstract] [Full Text] [Related]

  • 7. [Treatment of essential thrombocythemia].
    Alvarez-Larrán A, Cervantes F, Besses C.
    Med Clin (Barc); 2013 Sep 21; 141(6):260-4. PubMed ID: 23490491
    [Abstract] [Full Text] [Related]

  • 8. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy.
    Palandri F, Catani L, Testoni N, Ottaviani E, Polverelli N, Fiacchini M, De Vivo A, Salmi F, Lucchesi A, Baccarani M, Vianelli N.
    Am J Hematol; 2009 Apr 21; 84(4):215-20. PubMed ID: 19208420
    [Abstract] [Full Text] [Related]

  • 9. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
    Cacciola RR, Di Francesco E, Pezzella F, Tibullo D, Giustolisi R, Cacciola E.
    Acta Haematol; 2007 Apr 21; 118(4):215-8. PubMed ID: 18057866
    [No Abstract] [Full Text] [Related]

  • 10. Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.
    Samuelson B, Chai-Adisaksopha C, Garcia D.
    J Thromb Thrombolysis; 2015 Nov 21; 40(4):474-9. PubMed ID: 25894476
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
    Barbui T, Finazzi G, Dupuy E, Kiladjian JJ, Brière J.
    Leuk Lymphoma; 1996 Sep 21; 22 Suppl 1():149-60. PubMed ID: 8951786
    [Abstract] [Full Text] [Related]

  • 13. Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.
    Dingli D, Tefferi A.
    Curr Hematol Malig Rep; 2006 Jun 21; 1(2):69-74. PubMed ID: 20425334
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia.
    Weston H, Cowell V, Grimmett K, Saal R, Jones M, Mills T, Gill D, Marlton P, Bird R, Mollee P.
    Intern Med J; 2011 May 21; 41(5):408-15. PubMed ID: 20681956
    [Abstract] [Full Text] [Related]

  • 17. Evolving management of essential thrombocythaemia.
    Barbui T.
    Eur J Haematol Suppl; 2007 Oct 21; (68):22-3. PubMed ID: 17727561
    [No Abstract] [Full Text] [Related]

  • 18. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Gerli G, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Marchioli R, Leone G, Barbui T, GIMEMA CMD-Working Party.
    Haematologica; 2008 Mar 21; 93(3):372-80. PubMed ID: 18268279
    [Abstract] [Full Text] [Related]

  • 19. A critical review of anagrelide therapy in essential thrombocythemia and related disorders.
    Dingli D, Tefferi A.
    Leuk Lymphoma; 2005 May 21; 46(5):641-50. PubMed ID: 16019501
    [Abstract] [Full Text] [Related]

  • 20. Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
    Dombi P, Illés Á, Demeter J, Homor L, Simon Z, Karadi E, Udvardy M, Egyed M.
    Eur J Haematol; 2017 Feb 21; 98(2):106-111. PubMed ID: 27557754
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.